Angiotensin-converting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 2, 2011, Pages

  Becari, Christiane ^a   Teixeira, Felipe R ^b   Oliveira, Eduardo B ^b   Salgado, Maria Cristina O ^a  

^a Departments of Pharmacology   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chymostatin; Enalapril; Serine protease

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; CAPTOPRIL; CHYMOSTATIN; DIPEPTIDYL CARBOXYPEPTIDASE; ELASTASE; ELASTASE II; ENALAPRIL; LOSARTAN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CAROTID ARTERY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANALYSIS OF VARIANCE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; ENALAPRIL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED SHR; RATS, WISTAR; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TIME FACTORS; UP-REGULATION; VASOCONSTRICTION;

EID: 79961097301     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00534.2010     Document Type: Article

References (39)

1. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med 86: 615-621, 2008.
2. Becari C, Sivieri DO, Jr, Santos CF, Moysés MK, Oliveira EB, Salgado MCO. Role of elastase-2 as an angiotensin II-forming enzyme in rat carotid artery. J Cardiovasc Pharmacol 46: 498-504, 2005.
3. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4: 966-972, 1982.
4. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta 1480: 245-257, 2000.
5. Cornish KG, Joyner WL, Gilmore JP. Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res 44: 540-544, 1979.
6. Dzau VJ, Burt DW, Pratt RE. Molecular biology of the renin-angiotensin system. Am J Physiol Renal Fluid Electrolyte Physiol 255: F563-F573, 1988.
7. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997.
8. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605-2610, 2005.
9. Giani JF, Gironacci MM, Munoz MC, Turyn D, Dominici FP. Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. Exp Physiol 93: 570-578, 2008.
10. Gunther S, Gimbrone MA, Jr, Alexander RW. Regulation by angiotensin II of its receptors in resistance blood vessels. Nature 287: 230-232, 1980.
11. Hoit BD, Shao Y, Kinoshita A, Gabel M, Husain A, Walsh RA. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest 95: 1519-1527, 1995.
12. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32: 387-392, 1998.
13. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16: 564 -572, 1990.
14. Kinoshita A, Urata H, Bumpus FM, Husain A. Measurement of angiotensin I converting enzyme inhibition in the heart. Circ Res 73: 51-60, 1993.
15. Kohlstedt K, Busse R, Fleming I. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension 45: 126-132, 2005.
16. Ku E, Park J, Vidhun J, Campese Vl. The hazards of dual reninangiotensin blockade in chronic kidney disease. Arch Intern Med 169: 1015-1018, 2009.
17. Kunori Y, Muroga Y, Iidaka M, Mitsuhashi H, Kamimura T, Fukamizu A. Species differences in angiotensin II generation and degradation by mast cell chymases. J Recept Signal Transduct Res 25: 35-44, 2005.
18. Le Trong H, Neurath H, Woodbury RG. Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci USA 84: 364-367, 1987.
19. Leite R, Salgado MCO. Increased vascular formation of angiotensin II in one-kidney, one clip hypertension. Hypertension 19: 575-581, 1992.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-C(T)] method. Methods 25:402-408, 2001.
21. McDonald JE, Padmanabhan N, Petrie MC, Hillier C, Connell JMC, McMurray JJV. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro11D-Ala12] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ACE production of angiotensin II in humans. Circulation 104: 1805-1808, 2001.
22. Naito Y, Tsujino T, Fujioka Y, Ohyanagi M, Iwasaki T. Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats. Hypertension 40: 827-833, 2002.
23. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 149: 1186-1192, 1987.
24. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803, 2006.
25. Paula CA, Sousa MV, Salgado MCO, Oliveira EB. Purification and substrate specificity of an angiotensin converting elastase-2 from the rat mesenteric arterial bed perfusate. Biochim Biophys Acta 1388: 227-238, 1998.
26. Pereira HJ, Souza LL, Salgado MC, Oliveira EB. Angiotensin processing is partially carried out by carboxypeptidases in the rat mesenteric arterial bed perfusate. Regul Pept 151: 135-138, 2008.
27. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 37: 1056-1061, 2001.
28. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin ii receptor blockers plus angiotensinconverting enzyme inhibitors for left ventricular dysfunction. A quantitative review of data from randomized clinical trials. Arch Intern Med 167: 1930-1936, 2007.
29. Porritt MJ, Chen M, Rewell SS, Dean RG, Burrell LM, Howells DW. ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity. J Cereb Blood Flow Metab 30: 1520-1526, 2010
30. Rice IG, Thomas DA, Grant PJ, Turner AL. Evaluation of angiotensinconverting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383: 45-51, 2004.
31. Richard V, Hurel-Merle S, Scalbert E, Ferry G, Lallemand F, Bessou JP, Thuillez C. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 104: 750-752, 2001.
32. Santos CF, Oliveira EB, Salgado MCO, Greene AS. Molecular cloning and sequencing of the cDNA for rat mesenteric arterial bed elastase-2, an angiotensin II-forming enzyme. J Cardiovasc Pharmacol 39: 628-635, 2002.
33. Santos CF, Paula CA, Salgado MCO, Oliveira EB. Kinetic characterization and inhibition of the rat MAB elastase-2, an angiotensin I-converting serine protease. Can J Physiol Pharmacol 80: 42-47, 2002.
34. Santos CF, Caprio MAV, Oliveira EB, Salgado MCO, Schippers DN, Munzenmaier DH, Greene AS. Functional role, cellular source, and tissue distribution of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol 285: H775-H783, 2003.
35. Urata H, Healy B, Stewart RW, Bumpus FM, Hussain A. Angiotensin II-forming pathways in normal and failing heart. Circ Res 66: 883-890, 1990.
36. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265: 22348-22357, 1990.
37. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shi K, Takahashi Y, Saku K, Urata H, Dell'Italia LJ, Husain A. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 120: 1229-1239, 2010.
38. Wintroub BU, Schechter NB, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human and rat chymotryptic proteinases. J Invest Dermatol 83: 336-339, 1984.
39. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 80: 219-227, 1997.